Advertisement


Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Survival Outcomes and Clinical and Molecular Features

2019 Multidisciplinary Thoracic Cancers Symposium

Advertisement

Ruqin Chen, MB, of the Mayo Clinic Florida, discusses early study findings that show molecular profiling with NF1, CD79a, and AKT3 could potentially improve prediction of progression-free survival in patients with lung cancer who are receiving immunotherapy.



Related Videos

Lung Cancer

Susan Y. Wu, MD, on Non–Small Cell Lung Cancer: Using an Online Tool in Treatment

Susan Y. Wu, MD, of the University of California, San Francisco, discusses how patient exposure to treatment guidelines improved smoking cessation c...

Lung Cancer
Issues in Oncology

Shraddha M. Dalwadi, MD, MBA, on Non–Small Cell Lung Cancer: What Contributes to Disparities in Treating Stage I Disease

Shraddha M. Dalwadi, MD, MBA, of Baylor College of Medicine, discusses the nearly 12% of potentially curable patients with stage I NSCLC who do not ...

Immunotherapy

Martin Edelman, MD, on Immunotherapy: How Safe Is It for Patients With Autoimmune Disease?

Martin Edelman, MD, of Fox Chase Cancer Center, discusses the limited retrospective data that indicate some patients with cancer and autoimmune dise...

Lung Cancer
Symptom Management

Mark K. Ferguson, MD, on Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes

Mark K. Ferguson, MD, of the University of Chicago Hospital, discusses frailty and loss of muscle tissue, which are common among patients with lung cancer. These conditions a...

Lung Cancer
Neuroendocrine Tumors

Aaron S. Mansfield, MD, on Treating Rare Thoracic Cancers: Status Update

Aaron S. Mansfield, MD, of the Mayo Clinic, summarizes a session he moderated on rare thoracic cancers such as mesothelioma and thymic epithelial tumors, as well as novel ima...

Advertisement

Advertisement



;
Advertisement